Mahri Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahri Park has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- David Robert Spring
Yusuf Hamied Department of Chemistry University of Cambridge Cambridge UK
4 shared publications - Thomas Wharton
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
3 shared publications - Friederike M. Dannheim
Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
2 shared publications Jason S. Carroll
Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 ORE, UK
2 shared publications- Stephen J. Walsh
Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
2 shared publications - Andrew James Counsell
Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (27) , 13454-13464
Boosting peptide half-life: enabling efficient generation of Fc–peptide conjugates
Herein, we report a semi-synthetic strategy for generating Fc–peptide conjugates via disulfide re-bridging linker bioconjugation that retained biological activity in vitro and exhibited prolonged circulation in vivo .
- 29 May 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (27) , 13454-13464
Open AccessBoosting peptide half-life: enabling efficient generation of Fc–peptide conjugates
Herein, we report a semi-synthetic strategy for generating Fc–peptide conjugates via disulfide re-bridging linker bioconjugation that retained biological activity in vitro and exhibited prolonged circulation in vivo .
- Open Access
- 3 December 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (5) , 2722-2731
MMP-cleavable linker platform for tumour-responsive homo- and heterobivalent antibody–drug conjugates
Herein we report the development of a novel linker platform for tumour-responsive antibody–drug conjugates.
- 3 December 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (5) , 2722-2731
Open AccessMMP-cleavable linker platform for tumour-responsive homo- and heterobivalent antibody–drug conjugates
Herein we report the development of a novel linker platform for tumour-responsive antibody–drug conjugates.
- Open Access
- 28 October 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (95) , 18902-18905
Towards a glutathione-cleavable azobenzene linker for antibody–drug conjugates
Herein we describe the development of a novel azobenzene-containing glutathione-cleavable linker for use in antibody–drug conjugates (ADCs).
- 28 October 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (95) , 18902-18905
Open AccessTowards a glutathione-cleavable azobenzene linker for antibody–drug conjugates
Herein we describe the development of a novel azobenzene-containing glutathione-cleavable linker for use in antibody–drug conjugates (ADCs).
- Open Access
- 12 June 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (55) , 7025-7028
Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs
We describe a versatile and tuneable thiol responsive linker system using thiovinylketones, that relies on the conjugate addition–elimination mechanism of Michael acceptors for the traceless release of therapeutics.
- 12 June 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (55) , 7025-7028
Open AccessTuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs
We describe a versatile and tuneable thiol responsive linker system using thiovinylketones, that relies on the conjugate addition–elimination mechanism of Michael acceptors for the traceless release of therapeutics.